Mo, here we are again, this time I have a decent position. Been trading it, this time looks more like a hold. Averaged down recently, now under 2.50. Easy double but likely triple.
Before trial news, partnership news, or new analyst reports, our stock price has little stability and it will just trade without trending, expect it, just don't make ant short term plans for your invested funds here. You just don't want to be out of the name when they start releasing their data.
That's it, for our enjoyment and personal gratification. I like the values you mention, and will keep reading your posts, I like your positivity. Partnership? Bring it on!
One thing about soon is you can't be as wrong by saying it, since it's not on anyone's calendar system. I don't think "by the end of the year" is in anyone's mind as "soon" so why even post it? Hey, I'm long here like you are, but what good does this do? Wishing won't make it happen, there isn't a fact associated with your opinion, it's just an opinion. Do you think Baker Bros would (even privately) say such a thing? If you're just having fun, okay, but raising everyone's expectations without justification may lead to disappointment, and shares held for short term loss. We don't want that kind of trader here. At the quarterly conference call, maybe there will be mention of something by management that could send shares higher. That's my hope, but I can't predict so I'm not going to say it.
This hasn't been reported here on YMB so thanks for being on it. The event took place in March, so the factoid didn't create any interest in the market. We are drifting lower--the chart seems to indicate we've got more weakness ahead. Here's an expanded view of that announcement: ALLENDALE, N.J., March 24, 2015 /PRNewswire/ -- Stryker Corporation's Spine and Trauma & Extremities Divisions will be launching BIO4™, the next generation viable bone matrix at booth #443 during the American Academy of Orthopaedic Surgeons Annual Meeting in Las Vegas, NV from March 24-28th.
From the creators of the original allograft cellular bone matrix, Osiris Therapeutics, Inc., comes the next generation, BIO4, a viable bone matrix containing endogenous bone forming cells including mesenchymal stem cells, osteoprogenitor cells, osteoblasts, osteoinductive and angiogenic growth factors. BIO4 possesses all four characteristics involved in bone repair and regeneration: osteoconductive, osteoinductive, osteogenic and angiogenic.1, 2 It is a safe alternative to bone autograft that minimizes the potential for harvest site co-morbidities3.
"With the introduction of BIO4, Stryker now plays in the growing $199M4 Cellular Allograft Market," said Spencer Stiles, President, Stryker Spine. "Stryker offers one of the most comprehensive biologics portfolios on the market featuring the #1 selling synthetic bone graft5, Vitoss, and the next generation viable bone matrix, BIO4."
After this week's carnage in IDRA, my position here is now threatening red within a dime. I had an enormous trading profit that I let escape, wasn't expecting this much of a collapse! Pullback doesn't describe what happened here. Good luck friends, shorties take yours and let it recover!
Today's price action of the continued downtrend is but blip on the screen in the big picture, yet it is real money. Got to manage your emotions and keep your eye on the prize, especially hard on you if you had big gains and watched them disappear (we beat ourselves up over this missed opportunity using hindsight). I think this bleed will stop at $3.27 worst case, which is the 250-dma. On March 27th, intra-day lows reached $3.25, or the 250-dma, and it bounced right back up into the $3.80's. These development stage companies are difficult to hold for long term gains if you watch them too closely.
Jackie, your headline is misleading, the stock is actually down today over 3%now, after an early pop this morning. No doubt, point well taken, what a nice call!
We have to keep reminding ourselves why we invested, since the stock is flagging amidst an otherwise bullish backdrop in biotech. Thanks Lube.
Bluebird Bio sure inspires huge forward value for our MSTX shares, given what the market hopes will develop there, and their candidate potentially is a game changer but years out, maybe in 2020 they succeed in bringing LentiGlobin to market. Their market cap is over $4B now, trading around $134 a share.
I own 60k shares here so it's part of my 2015 investment thesis. I am glad however it's just a piece of my entire portfolio though, because it isn't producing a return as yet. I am down 9 per cent, but by q1 that will have faded in the run we will have had by then. I like our chances, just don't like the stock action. It keeps getting slammed down.
Anyone watching this right shoulder? I tell you, we're trending up, there's got to be some news about to break driving this much, much higher! 6-bagger in 3 years to $20 per share.
It's been over 100 days of sideways trading, so the supporting base for the launch is surely built and now reinforced. We know there's a lot of action behind the curtain, will be great to see the new cast of characters make their contributions to EPS and pps.
Agree. Mush brain, nonsensical posts, irrelevant to what happens here, or what people are interested in reading.
SYN is an emerging biopharmaceutical company listed on the NYSE. It is developing Trimesta for Multiple Sclerosis (MS), which is currently entering Phase 3, as well as multiple other drugs indicated for the anti-infective space. These include drugs targeting C. diff, Irritable Bowel Syndrome (IBS), and Pertussis - all of which are largely untapped markets worth billions to any company that successfully penetrates them. Without getting into the science of each drug, it is important to note that we believe the pipeline is validated, to some extent, by major interest in SYN from Intrexon Corporation (NYSE:XON) and Randall J. Kirk, Founder and CEO of XON and a widely known billionaire biotech guru. In fact, XON is partnered with SYN to advance SYN-004, which is currently under Phase 2a study with results expected later this year.
While we have previously offered support for a long-term buy thesis on SYN, accessible here, we have never offered support for a short-term buy thesis. Accordingly, it seems that the market has neglected to comprehensively grasp the value potential of the upcoming partnership announcement expected in Q2 2015. At this time, SYN is expected to announce it has partnered its Trimesta program, as CEO Jeff Riley has repeatedly stated in recent months that several partnership discussions are already underway - with the stated goal of closing a deal in Q2. We believe any partnership for Trimesta is likely to offer very large incentives to SYN in the form of upfront fees and milestone and royalty payments. In conjunction, we see a move to the mid $3s to low $4s. So, even if you don't understand its pipeline (which is highly diversified and deeply rooted in multiple high-value indications), simply invest in SYN for the hype that is expected to drive shares higher as we approach Q2. In the meantime, we see shares rising to at least the $3 range before a partnership is announced. Consensus estimates for SYN as formulated by TipRanks support 65% upside in 12 months. This supports our buy thesis and corroborates our price target range.
Remember, 3 in 3. It takes patience and time for a crop of young drugs to mature in a pipeline. $3 in 2018! Got that idea here from one of our faithful longs. Good luck working on that!